Sustained remission with the kinase inhibitor sorafenib in stage IV metastatic adrenocortical carcinoma

Endocrine Practice

Volumn 16, Issue 3, 2010, Pages 441-445

  Butler, Charles ^a   Butler, William M ^b   Rizvi, Ali A ^c  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b South Carolina Oncology Associates   (United States)

^c UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

17 HYDROXYCORTICOSTEROID; 17 OXOSTEROID; ANDROSTENEDIONE; CORTICOTROPIN; DOPAMINE; ESOMEPRAZOLE; FUROSEMIDE; GLUCOSE; HYDROCORTISONE; IRBESARTAN; ISRADIPINE; LEVOTHYROXINE; METOPROLOL; MITOTANE; NORADRENALIN; NORMETADRENALIN; PHENOXYBENZAMINE; POTASSIUM; PRASTERONE SULFATE; ROSUVASTATIN; SORAFENIB; TESTOSTERONE; VASCULOTROPIN; ZOLPIDEM; BENZENESULFONIC ACID DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE;

ABDOMINAL DISTENSION; ABDOMINAL TENDERNESS; ACNE; ADRENAL CORTEX CARCINOMA; ADULT; ADVANCED CANCER; AFRICAN AMERICAN; ALCOHOL CONSUMPTION; ALOPECIA; ANDROGEN BLOOD LEVEL; ANDROSTENEDIONE BLOOD LEVEL; ANXIETY; ARTICLE; BODY MASS; BODY WEIGHT; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER REGRESSION; CANCER STAGING; CANCER SURGERY; CASE REPORT; CATECHOLAMINE URINE LEVEL; CLITORIS HYPERTROPHY; COMPUTER ASSISTED TOMOGRAPHY; CORTICOTROPIN BLOOD LEVEL; CUSHINGOID SYNDROME; DIARRHEA; DOPAMINE URINE LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG TREATMENT FAILURE; DYSLIPIDEMIA; FATIGUE; FEMALE; GASTROESOPHAGEAL REFLUX; GENITAL SYSTEM EXAMINATION; GLUCOSE BLOOD LEVEL; HAIR GROWTH; HAND FOOT SYNDROME; HEART PALPITATION; HEART RATE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYDROCORTISONE BLOOD LEVEL; HYDROCORTISONE URINE LEVEL; HYPERANDROGENISM; HYPERTENSION; HYPOTHYROIDISM; LAPAROSCOPIC SURGERY; LEG EDEMA; LIVER BIOPSY; LIVER METASTASIS; LUNG BIOPSY; LUNG METASTASIS; MICROSCOPY; MITOSIS RATE; MULTIMODALITY CANCER THERAPY; MUSCLE DEVELOPMENT; NEEDLE BIOPSY; NORADRENALIN URINE LEVEL; PHEOCHROMOCYTOMA; PHYSICAL EXAMINATION; POSTOPERATIVE PERIOD; POTASSIUM BLOOD LEVEL; STEROID URINE LEVEL; TESTOSTERONE BLOOD LEVEL; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR NECROSIS; VAGINA DISEASE; VIRILIZATION; WEIGHT GAIN; METASTASIS; MIDDLE AGED; PATHOLOGY;

ADRENOCORTICAL CARCINOMA; BENZENESULFONATES; FEMALE; HUMANS; MIDDLE AGED; PROTEIN KINASE INHIBITORS; PYRIDINES;

EID: 77956634862     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/EP09295.CR     Document Type: Article

References (19)

1. Golden SH, Robinson KA, Saldanha I, Anton B, Ladenson PW. Clinical review: Prevalence and incidence of endocrine and metabolic disorders in the United States: A comprehensive review. J Clin Endocrinol Metab. 2009;94:1853-1878.
2. Patalano A, Brancato V, Mantero F. Adrenocortical cancer treatment. Horm Res. 2009;71(Suppl 1):99-104.
3. Delellis RA, Lloyd RV, Heitz PU, Eng C, eds. Pathology and Genetics of Tumours of Endocrine Organs. World Health Organization Classification of Tumors. Vol 8. World Health Organization Press, 2004: 136.
4. Terzolo M, Berruti A. Adjunctive treatment of adrenocortical carcinoma. Curr Opin Endocrinol Diabetes Obes. 2008;15:221-226. (Pubitemid 351595185)
5. Fassnacht M, Allolio B. Clinical management of adrenocortical carcinoma. Best Pract Res Clin Endocrinol Metab. 2009;23:273-289.
6. ClinicalTrials.gov Web site. Trial in Locally Advanced and Metastatic Adrenocortical Carcinoma Treatment (FIRMACT). Available at http:// clinicaltrials.gov/ct2/show/NCT00094497. Accessed September 24, 2009.
7. Berruti A, Ferrero A, Sperone P, et al. Emerging drugs for adrenocortical carcinoma. Expert Opin Emerg Drugs. 2008;13:497-509.
8. Quinkler M, Hahner S, Wortmann S, et al. Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine. J Clin Endocrinol Metab. 2008;93:2057-2062. (Pubitemid 351831515)
9. Volante M, Buttigliero C, Greco E, Berruti A, Papotti M. Pathological and molecular features of adrenocortical carcinoma: An update. J Clin Pathol. 2008;61:787-793. (Pubitemid 351969722)
10. Grötzinger J. Molecular mechanisms of cytokine receptor activation. Biochim Biophys Acta. 2002;1592:215-223. (Pubitemid 35284880)
11. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64:7099-7109. (Pubitemid 39331023)
12. Lee JO, Lee KW, Kim CJ, et al. Metastatic adrenocortical carcinoma treated with sunitinib: A case report. Jpn J Clin Oncol. 2009;39:183-185.
13. Negrier S, Jäger E, Porta C, et al. Efficacy and safety of sorafenib in patients with advanced renal cell carcinoma with and without prior cytokine therapy, a subanalysis of TARGET. Med Oncol. 2009;Sep 12. [Epub ahead of print].
14. Llovet JM, Ricci S, Mazzaferro V, et al; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378-390.
15. Heikkilä P, Arola J, Voutilainen R, Salmenkivi K, Kahri AI, Liu J. Expression of vascular endothelial growth factor in human adrenals. Endocr Res. 2000;26:867-871. (Pubitemid 32053113)
16. Zacharieva S, Atanassova I, Orbetzova M, et al. Circulating vascular endothelial growth factor and active renin concentrations and prostaglandin E2 urinary excretion in patients with adrenal tumours. Eur J Endocrinol. 2004;150:345-349. (Pubitemid 38443785)
17. de Fraipont F, El Atifi M, Gicquel C, Bertagna X, Chambaz EM, Feige JJ. Expression of the angiogenesis markers vascular endothelial growth factor-A, thrombospondin-1, and platelet-derived endothelial cell growth factor in human sporadic adrenocortical tumors: Correlation with genotypic alterations. J Clin Endocrinol Metab. 2000;85:4734-4741. (Pubitemid 32157660)
18. Kolomecki K, Stepien H, Bartos M, Kuzdak K. Usefulness of VEGF, MMP-2, MMP-3 and TIMP-2 serum level evaluation in patients with adrenal tumours. Endocr Regul. 2001;35:9-16. (Pubitemid 33711948)
19. Kirschner LS. Emerging treatment strategies for adrenocortical carcinoma: A new hope. J Clin Endocrinol Metab. 2006;91:14-21. (Pubitemid 43069108)